GEA 408
Alternative Names: GEA-408Latest Information Update: 12 Jul 2022
At a glance
- Originator GenEros BioPharma
- Class Antipsoriatics; Antirheumatics; Skin disorder therapies
- Mechanism of Action Signal transducing adaptor protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psoriasis; Psoriatic arthritis
Most Recent Events
- 20 Jun 2022 Phase-I clinical trials in Psoriasis in China (unspecified route) (GenEros Biopharma pipeline, June 2022)
- 20 Jun 2022 Phase-I clinical trials in Psoriatic arthritis in China (unspecified route) (GenEros Biopharma pipeline, June 2022)
- 19 Jun 2022 Preclinical trials in Psoriasis in China (unspecified route) (GenEros Biopharma pipeline, June 2022)